Le Lézard
Classified in: Health, Science and technology
Subject: PER

Teon Therapeutics Appoints Glen Giovannetti as Independent Board Member


SAN FRANCISCO, Jan. 12, 2021 /PRNewswire/ -- Teon Therapeutics, a private biopharmaceutical company developing a focused portfolio of small molecules that modulate metabolic signaling pathways in the tumor microenvironment, today announced the appointment of Glen Giovannetti, to its board of directors. Glen brings over 36 years of leadership success, industry expertise and board governance credentials following his retirement from EY (Ernst & Young) in December 2020. As EY's former Global Biotechnology and Life Sciences Leader, Glen has deep life sciences knowledge and financial governance, risk and reporting expertise. "We are excited to have Glen joining our board," said Ken Horne, President and Chief Operating Officer of Teon Therapeutics. "His experience as lead partner on numerous IPOs and M&A transactions in the biotech industry will be invaluable for Teon as we navigate future growth opportunities."

"I am looking forward to working with the Teon team," said Glen. "Adenosine receptors have already shown potential in the clinic in solid tumors, and Teon has assembled an excellent team with substantial expertise in this area. I look forward to lend my experience to the team." Glen joins a board that includes Feng Deng, Founding Managing Director of Northern Light Ventures, Lou Lange, MD, PhD, as well as Lina Yao, MD, PhD and Ken Horne from Teon Therapeutics.

About Teon Therapeutics
Teon Therapeutics is a private biopharma start-up developing a focused portfolio of small molecules that modulate metabolic signaling pathways in the tumor microenvironment. Teon's lead program is an A2BR-specific antagonist that will enter Phase1b trials in 2021. The experienced leadership team are experts in adenosine and GPCR therapeutics and led the development of Lexiscan® and Ranexa®, which contributed to the acquisition of CV Therapeutics by Gilead.

For more information please visit: www.teontherapeutics.com

Contact: [email protected] 

SOURCE Teon Therapeutics, Inc.


These press releases may also interest you

at 11:50
The "New Frontier: Significant Advancements in Handheld Gaming PCs" report has been added to ResearchAndMarkets.com's offering. This report delves into the product design of handheld gaming PCs and examines their potential future development. In...

at 11:45
The "U.S. Augmented and Virtual Reality Headset Market - A Country Analysis: Focus on Application, Product, and Country - Analysis and Forecast, 2024-2033" report has been added to  ResearchAndMarkets.com's offering. The U.S. augmented and virtual...

at 11:40
BiaTech Corporation today announced it has joined NVIDIA Inception, a program that nurtures startups revolutionizing industries with technological advancements. BiaTech is focused on AI-enabled edge and cloud technology for clean energy and utility...

at 11:32
Demandbase, the leader in AI-driven account-based go-to-market (GTM), today announced that it has not only been recognized as a leader in numerous G2 Spring Reports, it has also achieved a highly coveted placement on G2's Best Marketing & Digital...

at 11:25
The "Consumer Brain-Computer Interface: Market and Product Development Trends" report has been added to ResearchAndMarkets.com's offering. Over the past decade, brain-computer interface (BCI) technology has expanded beyond the confines of the...

at 11:25
Caravelle International Group , a global ocean technology company, today announced that it received a notice from The Nasdaq Stock Market LLC indicating that, as a result of not having timely filed its Annual Report on Form 20-F for the fiscal year...



News published on and distributed by: